Report "Pharma Automation Markets 2020"
World Market Report for Automation Hardware, Engineering, Services and Software in the Pharmaceutical Industries. This World Report analyzes and forecasts the development of the markets for automation in the pharma industries. Years covered: 2010, 2015, 2020.
Pharmaceutical automation hardware, software and services markets expected to show dynamic growth
Taking into account changing currency exchange rates over the forecast period, the global market for automation products and services for the pharmaceutical industry is predicted to grow from EUR 6.6 billion in 2010 to EUR 9.1 billion in 2015 and continue to grow to EUR 13.0 billion by 2020. This is equivalent to a compound average annual growth rate of 6.5% between 2010 and 2015 and of 7.4% between 2015 and 2020. For the entire forecasting period, the compound average annual growth rate is predicted to be 7.0%.
Rising production capacities in developed countries to allow for higher outputs, more innovative drugs and a growing diversity of preparations will stimulate automation demand for greenfield and brownfield projects worldwide. Growing need for rationalization investments represents a further stimulus for growing automation products and external services. Modernization investments represent an important stimulus for pharma automation markets as well. In developing and emerging countries, high plant capacity growth rates due to an increase in national demand are expected to generate rising demand for pharma automation hardware, software and services. Major pharmaceutical companies continue to outsource production capacities. Various greenfield and brownfield projects in these countries are arising, especially in India, China and Southeast Asia.
Forecast of Global Pharma Automation Markets until 2020: Subdivision by Automation Hardware, Software and External Services
2010 – EUR 6.6 Billion
2020 – EUR 13.0 Billion
Technology Trends
The pharmaceutical industry is a typical hybrid industry with batch and/or continuous as well as discrete manufacturing processes. Accordingly, automation products and systems required by the pharmaceutical industry comprise process as well as discrete automation technologies. Process automation is applied in active pharmaceutical ingredients (API) manufacturing as well as in formulation. Discrete automation is of relevance in formulation as well as in packaging including labeling. Automation in pharmaceutical production facilities aims at increasing plant performance and product quality, complying with new regulations in an efficient way as well as improving asset effectiveness.
Pharmaceutical plants are getting smarter and safer due to microcontroller-based digital sensors and smart field instrumentation allowing for faster data exchange rates between automated production processes and business applications. Automation and smart instrumentation are expected to further increase productivity, safety and availability of pharmaceutical plants.
Predictive maintenance and condition-based monitoring of production equipment require more and smarter sensors and intelligent control algorithms. Besides sensor smartness, hygienic design, safety, accuracy and ease of maintenance are important requirements as well. Special automation solutions will be required for biopharmaceutical microreactors, multipurpose/multifunctional processes, disposable single-use bioreactors as well as for clean room and containment systems.
1. EXECUTIVE SUMMARY
1.1 Pharmaceutical Automation Markets
1.2 Technology Trends
1.3 Strategies
2. AIM AND SCOPE, DEFINITIONS, EXCLUSIONS
2.1 Aim and Scope
2.2 Definitions and Exclusions
2.2.1 Country Definitions and their Attribution to Regions
2.2.2 Production Values and Shipments
2.2.3 Capital Expenditures
2.2.4 Production Investments
2.2.5 Production Project Costs
2.2.6 Production Operating Expenses
2.3 Segmentation of Automation Markets
3. METHODOLOGY, ASSUMPTIONS AND SOURCES OF INFORMATION
3.1 Methodology
3.2 Important Assumptions
3.3 Sources of Information
4. AUTOMATION MARKETS FOR THE PHARMACEUTICAL INDUSTRY: OVERVIEW
4.1 Pharmaceutical Industry - Basics
4.1.1 Scope and Definitions
4.1.2 Industry Codes of Relevance
4.1.3 Processes Involved
4.1.4 Overall Trends in the Pharmaceutical Industry
4.1.5 Stimulating Factors and Barriers for Pharmaceutical Markets
4.2 Worldwide Production Development in the Pharmaceutical Industry until 2020
4.2.1 Overview
4.2.2 Active Pharmaceutical Ingredients (APIs)
4.2.3 Pharmaceutical Preparations (excl. APIs)s
4.2.4 Therapeutic Drugs
4.2.5 Diagnostic Drugs
4.3 Worldwide Development of Capital Expenditures in the Pharmaceutical Industry until 2020
4.3.1 Overview
4.3.2 Capital Expenditures for Synthetic & Botanical Pharmaceuticals
4.3.3 Capital Expenditures for Biologic Pharmaceuticals
4.3.4 Production Investments in Pharmaceuticals
4.3.5 Production Investments by Types of Investments
4.3.6 External Project and Maintenance Expenditures by Supplier Structure
4.4 Worldwide Market Development of Plant-Related Products and Services in the Pharmaceutical Industry until 2020
4.4.1 Share of Automation in the Pharmaceutical Industry: Project Costs
4.4.2 Plant Trends in the Pharmaceutical Industry
4.4.3 Automation Trends in the Pharmaceutical Industry
4.4.4 Worldwide Market Development of Automation for the Pharmaceutical Industry until 2020: Total Market/External Demand
4.4.5 Worldwide Market Development of Automation for the Pharmaceutical Industry until 2020: Total Market/External Demand
4.4.6 Worldwide Market Development of Automation for the Pharmaceutical Industry until 2020: Project Phase
4.4.7 Worldwide Market Development of Automation for the Pharmaceutical Industry until 2020: Operation Phase
4.4.8 Worldwide Market Development of Automation for the Pharmaceutical Industry until 2020 by Core and Auxiliary Processes
4.4.9 Worldwide Market Development of Automation Hardware for the Pharmaceutical Industry until 2020
4.4.10 Worldwide Market Development of Control Level Hardware for the Pharmaceutical Industry until 2020
4.4.11 Worldwide Market Development of Instrumentation Level Hardware for the Pharmaceutical Industry until 2020
4.4.12 Worldwide Market Development of Automation Software for the Pharmaceutical Industry until 2020
4.4.13 Worldwide Market Development of Automation Services for the Pharmaceutical Industry until 2020
4.4.14 Worldwide Market Development of Automation for the Pharmaceutical Industry until 2020 by Pharmaceutical Industry Subsectors until 2020
4.4.15 Worldwide Market Development of Automation for the Pharmaceutical Industry in 2010 by Distribution Channels
5. AUTOMATION MARKETS FOR FORMULATION & PACKAGING OF SYNTHETIC PATENTED DRUGS
5.2 Worldwide Development of Capital Expenditures and Production Investments for Formulation and Packaging of Synthetic Patented Drugs until 2020
5.3 Worldwide Market Development of Automation for Formulation and Packaging of Synthetic Patented Drugs until 2020
5.3.1 Worldwide Market Development of Automation for Formulation and Packaging of Synthetic Patented Drugs until 2020: Total Market/External Demand
5.3.2 Worldwide Market Development of Automation for Formulation and Packaging of Synthetic Patented Drugs until 2020: Total Market/External and Internal Demand
5.3.3 Worldwide Market Development of Automation for Formulation and Packaging of Synthetic Patented Drugs until 2020: Project Phase
5.3.4 Worldwide Market Development of Automation for Formulation and Packaging of Synthetic Patented Drugs until 2020: Operation Phase
5.3.5 Worldwide Market Development of Automation for Formulation and Packaging of Synthetic Patented Drugs until 2020 by Core and Auxiliary Processes
5.3.6 Worldwide Market Development of Automation Hardware for Formulation and Packaging of Synthetic Patented Drugs until 2020
5.3.7 Worldwide Market Development of Control Level Hardware for Formulation and Packaging of Synthetic Patented Drugs until 2020
5.3.8 Worldwide Market Development of Instrumentation Level Hardware for Formulation and Packaging of Synthetic Patented Drugs until 2020
5.3.9 Worldwide Market Development of Automation Software for Formulation and Packaging of Synthetic Patented Drugs until 2020
5.3.10 Worldwide Market Development of Automation Services for Formulation and Packaging of Synthetic Patented Drugs until 2020
6. AUTOMATION MARKETS FOR ACTIVE PHARMACEUTICAL INGREDIENTS OF SYNTHETIC PATENTED DRUGS
6.2 Worldwide Development of Capital Expenditures and Production Investments for APIs of Synthetic Patented Drugs until 2020
6.3 Worldwide Market Development of Automation for APIs of Synthetic Patented Drugs until 2020 Markets Strategies Technologies International
6.3.1 Worldwide Market Development of Automation for APIs of Synthetic tented Drugs until 2020: Total Market/External Demand
6.3.2 Worldwide Market Development of Automation for APIs of Synthetic tented Drugs until 2020: Total Market/External and Internal Demand
6.3.3 Worldwide Market Development of Automation for APIs of Synthetic tented Drugs until 2020: Project Phase
6.3.4 Worldwide Market Development of Automation for APIs of Synthetic Patented Drugs until 2020: Operation Phase
6.3.5 Worldwide Market Development of Automation for APIs of Synthetic tented Drugs until 2020 by Core and Auxiliary Processes
6.3.6 Worldwide Market Development of Automation Hardware for APIs of Synthetic Patented Drugs until 2020
6.3.7 Worldwide Market Development of Control Level Hardware for APIs of Synthetic Patented Drugs until 2020 219
6.3.8 Worldwide Market Development of Instrumentation Level Hardware for APIs of Synthetic Patented Drugs until 2020 220
6.3.9 Worldwide Market Development of Automation Software for APIs of Synthetic Patented Drugs until 2020 221
6.3.10 Worldwide Market Development of Automation Services for APIs of Synthetic Patented Drugs until 2020
7. AUTOMATION MARKETS FOR FORMULATION & PACKAGING OF SYNTHETIC GENERIC DRUGS
7.1 Worldwide Production Development of Synthetic Generic Drugs until 2020
7.2 Worldwide Development of Capital Expenditures and Production Investments for Formulation and Packaging of Synthetic Generic Drugs until 2020
7.3 Worldwide Market Development of Automation for Formulation and Packaging of Synthetic Generic Drugs until 2020
7.3.1 Worldwide Market Development of Automation for Formulation and Packaging of Synthetic Generic Drugs until 2020: Total Market/External Demand
7.3.2 Worldwide Market Development of Automation for Formulation and Packaging of Synthetic Generic Drugs until 2020: Total Market/External and Internal Demand
7.3.3 Worldwide Market Development of Automation for Formulation and Packaging of Synthetic Generic Drugs until 2020: Project Phase
7.3.4 Worldwide Market Development of Automation for Formulation and Packaging of Synthetic Generic Drugs until 2020: Operation Phase
7.3.5 Worldwide Market Development of Automation for Formulation and Packaging of Synthetic Generic Drugs until 2020 by Core and Auxiliary Processes
7.3.6 Worldwide Market Development of Automation Hardware for Formulation and Packaging of Synthetic Generic Drugs until 2020
7.3.7 Worldwide Market Development of Control Level Hardware for Formulation and Packaging of Synthetic Generic Drugs until 2020
7.3.8 Worldwide Market Development of Instrumentation Level Hardware for Formulation and Packaging of Synthetic Generic Drugs until 2020
7.3.9 Worldwide Market Development of Automation Software for Formulation and Packaging of Synthetic Generic Drugs until 2020
7.3.10 Worldwide Market Development of Automation Services for Formulation and Packaging of Synthetic Generic Drugs until 2020
8. AUTOMATION MARKETS FOR ACTIVE PHARMACEUTICAL INGREDIENTS OF SYNTHETIC GENERIC DRUGS
8.1 Worldwide Production Development of APIs for Synthetic Generic Drugs until 2020 (Open Market)
8.2 Worldwide Development of Capital Expenditures and Production Investments for APIs of Synthetic Generic Drugs until 2020
8.3 Worldwide Market Development of Automation for APIs of Synthetic Generic Drugs until 2020
8.3.1 Worldwide Market Development of Automation for APIs of Synthetic Generic Drugs until 2020: Total Market/External Demand
8.3.2 Worldwide Market Development of Automation for APIs of Synthetic Generic Drugs until 2020: Total Market/External and Internal Demand
8.3.3 Worldwide Market Development of Automation for APIs of Synthetic Generic Drugs until 2020: Project Phase
8.3.4 Worldwide Market Development of Automation for APIs of Synthetic Generic Drugs until 2020: Operation Phase
8.3.5 Worldwide Market Development of Automation for APIs of Synthetic Generic Drugs until 2020 by Core and Auxiliary Processes
8.3.6 Worldwide Market Development of Automation Hardware for APIs of Synthetic Generic Drugs until 2020
8.3.7 Worldwide Market Development of Control Level Hardware for APIs of Synthetic Generic Drugs until 2020
8.3.8 Worldwide Market Development of Instrumentation Level Hardware for APIs of Synthetic Generic Drugs until 2020
8.3.9 Worldwide Market Development of Automation Software for APIs of Synthetic Generic Drugs until 2020
8.3.10 Worldwide Market Development of Automation Services for APIs of Synthetic Generic Drugs until 2020
9. AUTOMATION MARKETS FOR TRADITIONAL DIAGNOSTIC DRUGS
9.1 Worldwide Production Development of Traditional Diagnostic Drugs until 2020
9.2 Worldwide Development of Capital Expenditures and Production Investments for Traditional Diagnostic Drugs until 2020
9.3 Worldwide Market Development of Automation for Traditional Diagnostic Drugs until 2020
9.3.1 Worldwide Market Development of Automation for Traditional Diagnostic Drugs until 2020: Total Market/External Demand
9.3.2 Worldwide Market Development of Automation for Traditional Diagnostic Drugs until 2020: Total Market/External and Internal Demand
9.3.3 Worldwide Market Development of Automation for Traditional Diagnostic Drugs until 2020: Project Phase
9.3.4 Worldwide Market Development of Automation for Traditional Diagnostic Drugs until 2020: Operation Phase
9.3.5 Worldwide Market Development of Automation for Traditional Diagnostic Drugs until 2020 by Core and Auxiliary Processes
9.3.6 Worldwide Market Development of Automation Hardware for Traditional Diagnostic Generic Drugs until 2020
9.3.7 Worldwide Market Development of Control Level Hardware for Traditional Diagnostic Generic Drugs until 2020
9.3.8 Worldwide Market Development of Instrumentation Level Hardware for Traditional Diagnostic Drugs until 2020
9.3.9 Worldwide Market Development of Automation Software for Traditional Diagnostic Drugs until 2020
9.3.10 Worldwide Market Development of Automation Services for Traditional Diagnostic Drugs until 2020
10. AUTOMATION MARKETS FOR FORMULATION & PACKAGING OF BIOPHARMACEUTICAL PATENTED DRUGS
10.1 Worldwide Production Development of Biopharmaceutical Patented Drugs until 2020
10.2 Worldwide Development of Capital Expenditures and Production Investments for Formulation and Packaging of Biopharmaceutical Patented Drugs until 2020
10.3 Worldwide Market Development of Automation for Formulation and Packaging of Biopharmaceutical Patented Drugs until 2020
10.3.1 Worldwide Market Development of Automation for Formulation and Packaging of Biopharmaceutical Patented Drugs until 2020: Total Market/External Demand
10.3.2 Worldwide Market Development of Automation for Formulation and Packaging of Biopharmaceutical Patented Drugs until 2020: Total Market/External and Internal Demand
10.3.3 Worldwide Market Development of Automation for Formulation and Packaging of Biopharmaceutical Patented Drugs until 2020: Project Phase
10.3.4 Worldwide Market Development of Automation for Formulation and Packaging of Biopharmaceutical Patented Drugs until 2020: Operation Phase
10.3.5 Worldwide Market Development of Automation for Formulation and Packaging of Biopharmaceutical Patented Drugs until 2020 by Core and Auxiliary Processes
10.3.6 Worldwide Market Development of Automation Hardware for Formulation and Packaging of Biopharmaceutical Patented Drugs until 2020
10.3.7 Worldwide Market Development of Control Level Hardware for Formulation and Packaging of Biopharmaceutical Patented Drugs until 2020
10.3.8 Worldwide Market Development of Instrumentation Level Hardware for Formulation and Packaging of Biopharmaceutical Patented Drugs until 2020
10.3.9 Worldwide Market Development of Automation Software for Formulation and Packaging of Biopharmaceutical Patented Drugs until 2020
10.3.10 Worldwide Market Development of Automation Services for Formulation and Packaging of Biopharmaceutical Patented Drugs until 2020
11. AUTOMATION MARKETS FOR ACTIVE PHARMACEUTICAL INGREDIENTS OF BIOPHARMACEUTICAL PATENTED DRUGS
11.1 Worldwide Production Development of APIs for Biopharmaceutical Patented Drugs until 2020 (Open Market)
11.2 Worldwide Development of Capital Expenditures and Production Investments for APIs of Biopharmaceutical Patented Drugs until 2020
11.3 Worldwide Market Development of Automation for APIs of Bio- pharmaceutical Patented Drugs until 2020
11.3.1 Worldwide Market Development of Automation for APIs of Biopharmaceutical Patented Drugs until 2020: Total Market/External Demand
11.3.2 Worldwide Market Development of Automation for APIs of Biopharmaceutical Patented Drugs until 2020: Total Market/External and Internal Demand
11.3.3 Worldwide Market Development of Automation for APIs of Biopharmaceutical Patented Drugs until 2020: Project Phase
11.3.4 Worldwide Market Development of Automation for APIs of Biopharmaceutical Patented Drugs until 2020: Operation Phase
11.3.5 Worldwide Market Development of Automation for APIs of Biopharmaceutical Patented Drugs until 2020 by Core and Auxiliary Processes
11.3.6 Worldwide Market Development of Automation Hardware for APIs of Biopharmaceutical Patented Drugs until 2020
11.3.7 Worldwide Market Development of Control Level Hardware for APIs of Biopharmaceutical Patented Drugs until 2020
11.3.8 Worldwide Market Development of Instrumentation Level Hardware for APIs of Biopharmaceutical Patented Drugs until 2020
11.3.9 Worldwide Market Development of Automation Software for APIs of Biopharmaceutical Patented Drugs until 2020
11.3.10 Worldwide Market Development of Automation Services for APIs of Biopharmaceutical Patented Drugs until 2020
12. AUTOMATION MARKETS FOR FORMULATION & PACKAGING OF BIOSIMILAR DRUGS
12.1 Worldwide Production Development of Biosimilar Drugs until 2020
12.2 Worldwide Development of Capital Expenditures and Production Investments for Formulation and Packaging of Biosimilar Drugs until 2020
12.3 Worldwide Market Development of Automation for Formulation and Packaging of Biosimilar Drugs until 2020
12.3.1 Worldwide Market Development of Automation for Formulation and Packaging of Biosimilar Drugs until 2020: Total Market/External Demand
12.3.2 Worldwide Market Development of Automation for Formulation and Packaging of Biosimilar Drugs until 2020: Total Market/External and Internal Demand
12.3.3 Worldwide Market Development of Automation for Formulation and Packaging of Biosimilar Drugs until 2020: Project Phase
12.3.4 Worldwide Market Development of Automation for Formulation and Packaging of Biosimilar Drugs until 2020: Operation Phase
12.3.5 Worldwide Market Development of Automation for Formulation and Packaging of Biosimilar Drugs until 2020 by Core and Auxiliary Processes
12.3.6 Worldwide Market Development of Automation Hardware for Formulation and Packaging of Biosimilar Drugs until 2020
12.3.7 Worldwide Market Development of Control Level Hardware for Formulation and Packaging of Biosimilar Drugs until 2020
12.3.8 Worldwide Market Development of Instrumentation Level Hardware for Formulation and Packaging of Biosimilar Drugs until 2020
12.3.9 Worldwide Market Development of Automation Software for Formulation and Packaging of Biosimilar Drugs until 2020
12.3.10 Worldwide Market Development of Automation Services for Formulation and Packaging of Biosimilar Drugs until 2020
13. AUTOMATION MARKETS FOR ACTIVE PHARMACEUTICAL INGREDIENTS OF BIOSIMILAR DRUGS
13.1 Worldwide Production Development of APIs for Biosimilar Drugs until 2020 (Open Market)
13.2 Worldwide Development of Capital Expenditures and Production Investments for APIs of Biosimilar Drugs until 2020
13.3 Worldwide Market Development of Automation for APIs of Bio- similar Drugs until 2020
13.3.1 Worldwide Market Development of Automation for APIs of Biosimilar Drugs until 2020: Total Market/External Demand
13.3.2 Worldwide Market Development of Automation for APIs of Biosimilar Drugs until 2020: Total Market/External and Internal Demand
13.3.3 Worldwide Market Development of Automation for APIs of Biosimilar Drugs until 2020: Project Phase
13.3.4 Worldwide Market Development of Automation for APIs of Biosimilar Drugs until 2020: Operation Phase
13.3.5 Worldwide Market Development of Automation for APIs of Biosimilar Drugs until 2020 by Core and Auxiliary Processes
13.3.6 Worldwide Market Development of Automation Hardware for APIs of Biosimilar Drugs until 2020
13.3.7 Worldwide Market Development of Control Level Hardware for APIs of Biosimilar Drugs until 2020
13.3.8 Worldwide Market Development of Instrumentation Level Hardware for APIs of Biosimilar Drugs until 2020
13.3.9 Worldwide Market Development of Automation Software for APIs of Bio- similar Drugs until 2020
13.3.10 Worldwide Market Development of Automation Services for APIs of Bio- similar Drugs until 2020
14. AUTOMATION MARKETS FOR MOLECULAR DIAGNOSTIC DRUGS
14.1 Worldwide Production Development of Molecular Diagnostic Drugs until 2020
14.2 Worldwide Development of Capital Expenditures and Production Investments for Molecular Diagnostic Drugs until 2020
14.3 Worldwide Market Development of Automation for Molecular Diagnostic Drugs until 2020
14.3.1 Worldwide Market Development of Automation for Molecular Diagnostic Drugs until 2020: Total Market/External Demand
14.3.2 Worldwide Market Development of Automation for Molecular Diagnostic Drugs until 2020: Total Market/External and Internal Demand
14.3.3 Worldwide Market Development of Automation for Molecular Diagnostic Drugs until 2020: Project Phase
14.3.4 Worldwide Market Development of Automation for Molecular Diagnostic Drugs until 2020: Operation Phase
14.3.5 Worldwide Market Development of Automation for Molecular Diagnostic Drugs until 2020 by Core and Auxiliary Processes
14.3.6 Worldwide Market Development of Automation Hardware for Molecular Diagnostic Generic Drugs until 2020
14.3.7 Worldwide Market Development of Control Level Hardware for Molecular Diagnostic Generic Drugs until 2020
14.3.8 Worldwide Market Development of Instrumentation Level Hardware for Molecular Diagnostic Drugs until 2020
14.3.9 Worldwide Market Development of Automation Software for Molecular Diagnostic Drugs until 2020
14.3.10 Worldwide Market Development of Automation Services for Molecular Diagnostic Drugs until 2020
15. AUTOMATION MARKETS FOR TRADITIONAL BIOLOGICALS
15.1 Worldwide Production Development of Traditional Biologicals until 2020
15.2 Worldwide Development of Capital Expenditures and Production Investments for Traditional Biologicals until 2020
15.3 Worldwide Market Development of Automation for Traditional Biologicals until 2020
15.3.1 Worldwide Market Development of Automation for Traditional Biologicals until 2020: Total Market/External Demand
15.3.2 Worldwide Market Development of Automation for Traditional Biologicals until 2020: Total Market/External and Internal Demand
15.3.3 Worldwide Market Development of Automation for Traditional Biologicals until 2020: Project Phase
15.3.4 Worldwide Market Development of Automation for Traditional Biologicals until 2020: Operation Phase
15.3.5 Worldwide Market Development of Automation for Traditional Biologicals until 2020 by Core and Auxiliary Processes
15.3.6 Worldwide Market Development of Automation Hardware for Traditional Biologicals Drugs until 2020
15.3.7 Worldwide Market Development of Control Level Hardware for Traditional Biologicals until 2020
15.3.8 Worldwide Market Development of Instrumentation Level Hardware for Traditional Biologicals until 2020
15.3.9 Worldwide Market Development of Automation Software for Traditional Biologicals until 2020
15.3.10 Worldwide Market Development of Automation Services for Traditional Biologicals until 2020
16. AUTOMATION MARKETS FOR OUTSOURCING FIRMS OF AUXILIARY PROCESSES
16.1 Basics and Definitions
16.2 Worldwide Market Development of Automation for Outsourcing Firms of Auxiliary Processes until 2020
16.2.1 Worldwide Market Development of Automation for Outsourcing Firms of Auxiliary Processes until 2020: Total Market/External Demand
16.2.2 Worldwide Market Development of Automation for Outsourcing Firms of Auxiliary Processes until 2020: Total Market/External and Internal Demand
16.2.3 Worldwide Market Development of Automation for Outsourcing Firms of Auxiliary Processes until 2020: Project Phase
16.2.4 Worldwide Market Development of Automation for Outsourcing Firms of Auxiliary Processes until 2020: Operation Phase
16.2.5 Worldwide Market Development of Automation for Outsourcing Firms of Auxiliary Processes until 2020 by Auxiliary Processes
16.2.6 Worldwide Market Development of Automation Hardware for Outsourcing Firms of Auxiliary Processes until 2020
16.2.7 Worldwide Market Development of Control Level Hardware for Outsourcing Firms of Auxiliary Processes until 2020
16.2.8 Worldwide Market Development of Instrumentation Level Hardware for Outsourcing Firms of Auxiliary Processes until 2020
16.2.9 Worldwide Market Development of Automation Software for Outsourcing Firms of Auxiliary Processes until 2020
16.2.10 Worldwide Market Development of Automation Services for Outsourcing Firms of Auxiliary Processes until 2020
Automation Segmentation
Automation hardware control level:
- HMI-devices: I-PCs, workstations, client servers, others
- Control devices: proprietary controls, PLC-based controls, PC-based controls (soft and slot PLCs), others
- Communication devices: field bus, Ethernet/TCP-IP, others
Automation hardware field level (instrumentation):
- Actuators
- Weighing systems
- Process analyzers
- Sensors and measuring instruments
Automation software:
Stand-alone software and embedded software
Services project phase:
Basic engineering, detail engineering, application engineering, assembly and installation, start-up and commissioning
Services operation phase:
Maintenance and repair services, adaptation and support services, training.
Automation services are further segmented into open-market and captive-market services.
Industries Covered
Segmentation of pharma automation markets and capital expenditure figures by the following pharma product sectors:
- Formulation and packaging for synthetic patented drugs
- APIs for synthetic patented drugs
- Formulation and packaging for synthetic generic drugs
- APIs for synthetic generic drugs
- Formulation and packaging for biopharmaceutical patented drugs
- APIs for biopharmaceutical patented drugs
- Formulation and packaging for biosimilar drugs
- APIs for biosimilar drugs
- Traditional biologicals
- Traditional diagnostic drugs
- Molecular diagnostic drugs
- Outsourcing firms for auxiliary processes.
Countries & Regions
* Background: The background calculations of this report are based on the analysis of 65 countries. However, only the countries/regions listed above are shown.
* Countries/regions shown in Report are:
- Western Europe: Germany, France, United Kingdom, Italy, Benelux, Scandinavia, Spain with Portugal, Rest of Western Europe
- Eastern Europe: Russia, Other Countries of the Former Soviet Union, Other Eastern European Countries including Turkey
- North America: USA, Rest of North America
- South America: Brazil, Rest of South America
- Asia Pacific: Japan, Australia, China, India, Rest of Asia Pacific
- Rest of the World.
Project versus Operation Phases
Core Processes versus Auxiliary Processes
For each pharma product sector, the automation markets are broken down into core and auxiliary processes:
- Core processes
- Packaging/filling
- Storage facilities
- Utilities
- Environmental facilities.
Methodology and Size of the Report
The methodology used to derive the global pharma automation market figures can be characterized as follows:
- It is model-based – this is necessary in order to handle the huge amount of data and the host of case distinctions concerning the various countries and pharma product sectors. By means of the model-based methodology, global pharma automation market figures can be determined and compared systematically for each industry and product sector, and traced back to their determining factors.
- It is reality-based in the sense that the results of the model are backed by expert interviews and a wealth of external statistics of the pharma industry.
- It is based on a bottom-up approach and a top-down approach at the same time, where both methods check and balance each other.
The World Report "Pharma Automation Markets 2020" is based on the analysis and forecast of worldwide capital expenditure figures, expert interviews and the analysis of more than 330 basic statistics, annual reports and trend analyses to underpin market figures: association statistics, country statistics, various analyses on sales figures, investment figures, machinery, electrical and automation statistics as well as a host of annual reports.
Automation market figures shown in the report cover project phase markets as well as market figures for the operation phase.
